JAN

• The offering included the full exercise of the underwriters' option to purchase 2,400,000 additional shares.
• The Underwriting Agreement, dated August 10, 2026, was entered into with BofA Securities, J.P. Morgan Securities, and Wells Fargo Securities as representatives of the underwriters.
• The offering was made pursuant to a Form S-11 registration statement (File No. 333-298182).
• The Underwriting Agreement contains customary representations, warranties, covenants, closing conditions, and indemnification obligations.

1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits

• Consolidated revenues increased 45% to $216 million, and Adjusted EBITDAre increased 34% to $79 million.
• FFO as Adjusted was $0.24 per diluted share, up 40% from $0.17 in the prior-year quarter.
• Same-store adjusted NOI grew 19.2% with margin expansion of 250 basis points.
• Full year 2026 guidance raised: diluted EPS to $0.34-$0.37, FFO as Adjusted to $0.95-$0.98, and same-store NOI growth to 13%-17%.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The underwriters were granted a 30-day option to purchase up to an additional 3,750,000 shares of Class A-1 common stock.
• The offering was made pursuant to a registration statement on Form S-11 (File No. 333-296384).
• The Underwriting Agreement, dated June 2, 2026, was entered into with BofA Securities, J.P. Morgan Securities, RBC Capital Markets, and Wells Fargo Securities as representatives of the underwriters.
• The Underwriting Agreement includes customary representations, warranties, covenants, closing conditions, indemnification obligations, and termination provisions.

1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits

• Diluted net loss of $(0.05) per share post-IPO and net income of $0.13 per share for the quarter.
• FFO as Adjusted of $0.23 per share increased 35%; same-store adjusted NOI increased 13.8% with margin expansion of 150 bps.
• Completed IPO in March 2026 with approximately $880 million net proceeds; acquired JV partner's 46.5% interest for $314 million and additional communities for ~$400 million.
• Full-year 2026 guidance: diluted EPS $0.23–$0.27, Nareit FFO per share $0.84–$0.88, FFO as Adjusted per share $0.93–$0.97, same-store NOI growth 11%–15%.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The company entered into an underwriting agreement with BofA Securities and J.P. Morgan Securities as representatives of the underwriters.
• Janus Living entered into an amended and restated operating agreement for its operating company, Janus Living OP, LLC, under which it owns a 71.1% interest and serves as managing member.
• The company entered into a management agreement with Healthpeak Investment Management, LLC, providing for an annual management fee of $10.0 million plus adjustments, with an initial three-year term.
• Janus Living entered into a $500 million revolving credit facility and a $100 million delayed-draw term loan facility, with an option to increase up to $1.5 billion in aggregate.
• The company entered into a stockholders agreement with Healthpeak, granting Healthpeak board designation rights based on ownership percentage, and a registration rights agreement covering 214,734,026 shares.
• Indemnification agreements were entered into with each director and executive officer, effective March 19, 2026.